HK1218385A1 - 作為 激酶調節劑的雜芳環化合物 - Google Patents

作為 激酶調節劑的雜芳環化合物

Info

Publication number
HK1218385A1
HK1218385A1 HK16106363.8A HK16106363A HK1218385A1 HK 1218385 A1 HK1218385 A1 HK 1218385A1 HK 16106363 A HK16106363 A HK 16106363A HK 1218385 A1 HK1218385 A1 HK 1218385A1
Authority
HK
Hong Kong
Prior art keywords
heteroaromatic compounds
kinase modulators
modulators
kinase
heteroaromatic
Prior art date
Application number
HK16106363.8A
Other languages
English (en)
Inventor
Ning Xi
Original Assignee
Calitor Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calitor Sciences Llc filed Critical Calitor Sciences Llc
Publication of HK1218385A1 publication Critical patent/HK1218385A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16106363.8A 2013-02-21 2016-06-03 作為 激酶調節劑的雜芳環化合物 HK1218385A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767721P 2013-02-21 2013-02-21
PCT/US2014/016643 WO2014130375A1 (en) 2013-02-21 2014-02-15 Heteroaromatic compounds as pi3 kinase modulators

Publications (1)

Publication Number Publication Date
HK1218385A1 true HK1218385A1 (zh) 2017-02-17

Family

ID=51351332

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106363.8A HK1218385A1 (zh) 2013-02-21 2016-06-03 作為 激酶調節劑的雜芳環化合物

Country Status (15)

Country Link
US (1) US9573953B2 (zh)
EP (1) EP2958564B1 (zh)
JP (1) JP6389829B2 (zh)
KR (1) KR102148681B1 (zh)
AU (1) AU2014219256B2 (zh)
BR (1) BR112015018318A2 (zh)
CA (1) CA2898294C (zh)
ES (1) ES2674705T3 (zh)
HK (1) HK1218385A1 (zh)
MX (1) MX2015010700A (zh)
MY (1) MY182036A (zh)
RU (1) RU2672910C9 (zh)
SG (1) SG11201505493QA (zh)
TW (1) TWI620749B (zh)
WO (1) WO2014130375A1 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108137607B (zh) 2015-08-26 2021-04-06 缆图药品公司 适用于治疗与ntrk相关的病症的化合物和组合物
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
EP3558991A2 (en) * 2016-12-23 2019-10-30 Plexxikon Inc. Compounds and methods for cdk8 modulation and indications therefor
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018169700A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
CN109867668B (zh) * 2017-12-02 2021-03-26 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867672B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 吡唑[1,5-a]吡啶衍生物的盐及其用途
CN109867671B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867669B (zh) * 2017-12-02 2021-02-26 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的晶型及其药物组合物和用途
CN109867670B (zh) * 2017-12-02 2020-07-07 广东东阳光药业有限公司 一种吡唑[1,5-a]吡啶化合物的单钠盐及其医药用途
EP3727379A4 (en) * 2017-12-20 2021-12-15 Sunshine Lake Pharma Co., Ltd. PYRAZOLO [1,5-A] PYRIDINE DERIVATIVE SALTS AND THEIR USE
WO2020078445A1 (zh) * 2018-10-19 2020-04-23 广东东阳光药业有限公司 一种治疗纤维化疾病的药物组合或药物组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
EP0734436B1 (en) 1993-11-30 1999-04-14 McGILL UNIVERSITY Inhibition of dna methyltransferase
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6268137B1 (en) 1996-05-22 2001-07-31 Methylgene, Inc. Specific inhibitors of DNA methyl transferase
US6020318A (en) 1997-05-30 2000-02-01 Methylgene, Inc. DNA methyltransferase genomic sequences and antisense oligonucleotides
JP2002512508A (ja) 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Dnaメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
US6066625A (en) 1998-02-03 2000-05-23 Methylgene, Inc. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
US6953783B1 (en) 1998-10-19 2005-10-11 Methylgene, Inc. Modulation of gene expression by combination therapy
JP2003500052A (ja) 1999-05-03 2003-01-07 メチルジーン インコーポレイテッド ヒストン脱アセチル酵素の抑制
CA2391952C (en) 1999-11-23 2012-01-31 Methylgene Inc. Inhibitors of histone deacetylase
JP2004533850A (ja) 2000-03-24 2004-11-11 メチルジーン・インコーポレーテッド 特異的なヒストン脱アセチル化酵素アイソフォームの阻害
WO2001070675A2 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
ES2366082T3 (es) * 2001-04-27 2011-10-17 EISAI R&D MANAGEMENT CO., LTD. Pirazolo 1,5-a piridinas y medicinas que las contienen.
EP1429765A2 (en) 2001-09-14 2004-06-23 Methylgene, Inc. Inhibitors of histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
EP1551795A1 (en) 2002-10-17 2005-07-13 Methylgene, Inc. Inhibitors of histone deacetylase
AU2003299651A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
ES2222813B1 (es) * 2003-07-24 2005-12-16 Ferrer Internacional, S.A. N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
US7329662B2 (en) 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
WO2005092899A1 (en) 2004-03-26 2005-10-06 Methylgene Inc. Inhibitors of histone deacetylase
BRPI0513982A (pt) 2004-07-30 2007-11-27 Methylgene Inc inibidores de sinalização de receptor de vegf e receptor de hgf
RU2412943C2 (ru) 2005-03-23 2011-02-27 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ АЦЕТИЛЕНИЛ-ПИРАЗОЛО-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
WO2009055418A1 (en) 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
WO2009085230A1 (en) * 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
WO2010118207A1 (en) 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
MY162604A (en) * 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
EP2608669B1 (en) * 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
CN102675286B (zh) 2011-03-07 2015-08-19 中国科学院上海药物研究所 一类吲唑类化合物及其制备方法、用途和药物组合物
CN103748099B (zh) * 2011-05-19 2016-08-17 卡洛斯三世国家癌症研究中心基金会 作为蛋白激酶抑制剂的大环化合物
WO2012174312A2 (en) 2011-06-15 2012-12-20 Glaxosmithkline Llc Benzimidazole derivatives as antiviral agents
KR101274986B1 (ko) 2011-07-27 2013-06-17 한국과학기술원 이미다조피리딘 유도체, 이를 포함하는 PI3K 및/또는 mTOR 저해제용 약학 조성물 및 PI3K 및/또는 mTOR과 연관된 질환 치료용 약학 조성물
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN102924450A (zh) 2012-11-01 2013-02-13 西安交通大学 6-(5-吡啶基)-1,2,4-三唑并吡啶类化合物及其制备方法和用途

Also Published As

Publication number Publication date
MX2015010700A (es) 2017-01-23
WO2014130375A1 (en) 2014-08-28
AU2014219256B2 (en) 2017-02-16
SG11201505493QA (en) 2015-08-28
ES2674705T3 (es) 2018-07-03
US9573953B2 (en) 2017-02-21
JP6389829B2 (ja) 2018-09-12
CA2898294A1 (en) 2014-08-28
KR102148681B1 (ko) 2020-08-27
US20140234254A1 (en) 2014-08-21
RU2672910C2 (ru) 2018-11-21
AU2014219256A1 (en) 2015-07-30
EP2958564A4 (en) 2016-10-26
KR20150118102A (ko) 2015-10-21
EP2958564B1 (en) 2018-05-09
CA2898294C (en) 2020-06-09
JP2016509056A (ja) 2016-03-24
TW201443049A (zh) 2014-11-16
EP2958564A1 (en) 2015-12-30
RU2015131467A (ru) 2017-03-24
MY182036A (en) 2021-01-18
BR112015018318A2 (pt) 2017-08-22
RU2672910C9 (ru) 2019-06-04
TWI620749B (zh) 2018-04-11

Similar Documents

Publication Publication Date Title
HK1218385A1 (zh) 作為 激酶調節劑的雜芳環化合物
HK1212694A1 (zh) 四氫吡咯並三嗪類化合物
GB201309085D0 (en) Compounds
GB201302927D0 (en) Compounds
HK1211578A1 (zh) 作為 激酶抑制劑的酰氨基咪唑並噠嗪
HK1221465A1 (zh) 新型雜環化合物
GB201311951D0 (en) Compounds
GB201309508D0 (en) Compounds
ZA201508864B (en) Substituted heterocyclic compounds as crac modulators
HK1212228A1 (zh) 乳化型外用組合物
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201317619D0 (en) Compounds
GB201312901D0 (en) Compounds
GB201311953D0 (en) Compounds
EP3010923A4 (en) PYRROLOCHINAZOLINVERBINDUNGEN
EP2948457A4 (en) COMPOUNDS
GB201316014D0 (en) Compounds
GB201310460D0 (en) Compounds
GB201306794D0 (en) Compounds
GB201313695D0 (en) Appetite-suppressant composition
GB201322028D0 (en) Compounds
GB201306013D0 (en) compensation
GB201318323D0 (en) Compounds
GB201318143D0 (en) Compounds
GB201317118D0 (en) Compounds